NasdaqCM - Nasdaq Real Time Price USD

Mustang Bio, Inc. (MBIO)

Compare
0.2798 -0.0142 (-4.83%)
At close: September 10 at 4:00 PM EDT
0.2730 -0.01 (-2.43%)
After hours: September 10 at 7:51 PM EDT
Loading Chart for MBIO
DELL
  • Previous Close 0.2940
  • Open 0.2887
  • Bid 0.2685 x 100
  • Ask 0.2822 x 200
  • Day's Range 0.2700 - 0.2936
  • 52 Week Range 0.1280 - 2.8130
  • Volume 720,667
  • Avg. Volume 11,127,429
  • Market Cap (intraday) 10.418M
  • Beta (5Y Monthly) 1.96
  • PE Ratio (TTM) --
  • EPS (TTM) -2.7200
  • Earnings Date Nov 12, 2024 - Nov 18, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 10.00

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

www.mustangbio.com

80

Full Time Employees

December 31

Fiscal Year Ends

Recent News: MBIO

View More

Performance Overview: MBIO

Trailing total returns as of 9/10/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

MBIO
79.27%
S&P 500
15.21%

1-Year Return

MBIO
89.44%
S&P 500
23.29%

3-Year Return

MBIO
99.35%
S&P 500
22.31%

5-Year Return

MBIO
99.55%
S&P 500
84.51%

Compare To: MBIO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: MBIO

View More

Valuation Measures

Annual
As of 4/4/2024
  • Market Cap

    10.95M

  • Enterprise Value

    7.76M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    31.75

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    -0.14

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -105.16%

  • Return on Equity (ttm)

    -1,191.31%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -32.06M

  • Diluted EPS (ttm)

    -2.7200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.27M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -11.5M

Research Analysis: MBIO

View More

Company Insights: MBIO

Research Reports: MBIO

View More

People Also Watch